Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2026-01-20 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司信息披露暂缓与豁免制度
Governance Information Classification · 95% confidence The document is a detailed internal policy and procedural manual regarding the company's information disclosure delay and exemption system. It includes definitions, scope, internal management procedures, forms for approval and registration, confidentiality commitments, and responsibilities related to delaying or exempting disclosure of sensitive information such as state secrets or commercial secrets. There are no financial statements, earnings data, or investor presentations. It is not an announcement of a report but a governance and compliance document outlining internal rules and procedures for information disclosure. Therefore, it fits best under Governance Information (CGR). The document length (5563 characters) and content confirm it is a substantive policy document, not a brief announcement or certification.
2026-01-20 Chinese
金陵药业股份有限公司关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting of shareholders (临时股东会) for Jinling Pharmaceutical Co., Ltd. It includes details about the meeting time, location, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is under 5,000 characters and primarily serves as a meeting notice and proxy solicitation. Therefore, it fits best under Proxy Solicitation & Information Statement (PSI).
2026-01-20 Chinese
金陵药业股份有限公司董事和高级管理人员离职管理制度
Board/Management Information Classification · 95% confidence The document is titled '董事和高级管理人员离职管理制度' which translates to 'Board and Senior Management Personnel Resignation Management System'. It details the rules, procedures, and responsibilities related to the resignation and departure of directors and senior management personnel. The content focuses on governance policies, legal compliance, and internal management related to board and management changes. There is no financial data, no report of financial results, no announcement of voting results, no legal proceeding updates, no capital or financing updates, and no mention of shareholder votes or dividends. The document is a governance-related internal policy document concerning board and management personnel changes. Therefore, it fits best under the category 'Board/Management Information (MANG)', which covers announcements or information about changes in the company's board of directors or senior management.
2026-01-20 Chinese
金陵药业股份有限公司第九届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and references to related disclosures. The content focuses on board decisions and governance matters rather than financial results or reports. There is no indication of financial statements or detailed management discussion. The document is not a report itself but an official announcement of board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is a meeting resolution announcement, not a full report or presentation.
2026-01-20 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the amounts, dates, expected yields, and risk control measures related to the company's use of idle raised funds for cash management. The document is relatively short (4100 characters) and focuses on updates about cash management activities rather than presenting comprehensive financial statements or full financial performance. It does not contain full financial reports or detailed financial analysis but rather an update on financing activities related to raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-12-29 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2025年第四次临时股东会的法律意见书
Regulatory Filings
2025-12-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.